WOBURN, Mass.--(BUSINESS WIRE)--Feb. 28, 2006--ArQule, Inc. (Nasdaq: ARQL) today announced the initiation of GLP toxicology studies with ARQ 171, the second compound generated through the Company's ARQ-550RP Activated Checkpoint Therapy(SM) (ACT) program, under its agreement with Roche.
